MOUNTAIN VIEW, Calif., Jan. 17 /PRNewswire/ -- ChemoCentryx, Inc. today announced the appointment of Edward E. Penhoet, Ph.D., to the company's Board of Directors. Dr. Penhoet is recognized for his 25 years of leadership and contributions in the public and private sectors of the life sciences industry, including as co-founder and Chief Executive Officer of Chiron Corporation (now Novartis).
Dr. Penhoet is currently the President of the Gordon and Betty Moore Foundation, overseeing the philanthropic activities of the Foundation since 2004. Dr. Penhoet has also held the position of Director with Alta Partners, a venture capital partnership investing in life science companies, since 2000. From 1998 to 2002, he served as Dean of the School of Public Health at the University of California, Berkeley. In 1981, Dr. Penhoet co-founded Chiron Corporation and served as its Chief Executive Officer until 1998. Prior to founding Chiron, he was a faculty member of the Biochemistry Department of U.C. Berkeley. Dr. Penhoet also serves as the Vice Chairman of the Independent Citizen's Oversight Committee of the California Institute for Regenerative Medicine which was created by the passage of Proposition 71, also known as the stem cell initiative.
A member of the Institute of Medicine of the National Academies of Sciences and a member of the American Society of Biological Chemists, Dr. Penhoet has co-authored more than 50 scientific articles and papers. In addition to ChemoCentryx, he serves as a Director of Zymogenetics, Scynexis, Metabolex and Renovis, Inc.
Dr. Penhoet earned his A.B. in biology from Stanford University, and his Ph.D. in biochemistry from the University of Washington. He was a post-doctoral fellow at the University of California, San Diego.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company
focused on discovering, developing and commercializing orally-administered
therapeutics that target th
'/>"/>
| SOURCE ChemoCentryx, Inc. Copyright©2008 PR Newswire. All rights reserved |